Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

a cutting-edge cancer diagnostic tool.

2.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

3.

AACR: American Association for Cancer Research

4.

Doctors say lung cancer is still the deadliest cancer, but hope is growing

5.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot